How Do You Use Ozempic for Weight Loss: Dosing Guide

Ozempic (semaglutide) is administered as a weekly subcutaneous injection, typically starting at 0.25 mg and titrating upward based on tolerability and response. The medication activates GLP-1 receptors in the brain and pancreas, reducing appetite and increasing satiety signaling.

Weight loss use of semaglutide represents a significant shift in how providers approach metabolic health, but outcomes vary widely among individuals. Understanding your own genetic and biomarker profile can help you and your provider determine whether semaglutide, a compounded alternative, or another approach aligns best with your health goals.

Standard Dosing Protocol and Titration Schedule

Semaglutide dosing for weight loss follows a structured escalation protocol to minimize gastrointestinal side effects. Most protocols begin at 0.25 mg weekly, increasing by 0.25 mg every four weeks until reaching a therapeutic dose of 1.0–2.4 mg weekly.

The four-week interval between dose increases allows your body to adapt and helps distinguish between temporary adjustment effects and true intolerance. Clinical evidence shows slower titration improves adherence and reduces discontinuation due to nausea or other GI symptoms.

Injection Technique, Storage, and Administration Details

Semaglutide is injected subcutaneously (under the skin) in the abdomen, thigh, or upper arm. Many patients rotate injection sites to reduce lipodystrophy risk. Pens or vials require refrigeration until first use, then can be stored at room temperature for up to 28 days.

Proper injection technique matters for consistent absorption and reduced injection-site reactions. Most patients receive training from a nurse or pharmacist and follow a standardized protocol to ensure accurate dosing and comfortable administration over time.

How Semaglutide Works: Mechanism and Expected Timeline

Semaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone that regulates blood glucose and appetite. It slows gastric emptying, increases feelings of fullness, and activates brain regions controlling hunger and reward-related eating behaviors.

Weight loss typically becomes measurable within 4–8 weeks, though significant changes may take 12–16 weeks. Clinical trials show average weight loss of 5–15% of baseline body weight over 68 weeks, with variability based on genetics, adherence, diet, and exercise.

Safety Considerations, Contraindications, and Who Should Not Use Semaglutide

Semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Common side effects include nausea, vomiting, diarrhea, and constipation, typically mild and transient but sometimes requiring dose adjustment.

Patients with severe kidney or liver disease, active diabetic retinopathy, or acute pancreatitis require medical evaluation before use. A qualified healthcare provider should assess your full medical history, medications, and metabolic markers before initiating semaglutide or any GLP-1 receptor agonist.

How PlexusDx Supports a More Personalized Approach

Your genetic profile in GLP-1 and GIPR signaling pathways may help provide context for how your body responds to semaglutide or other GLP-1 medications. PlexusDx's Precision Peptide Genetic Test examines variants like GLP1R rs6923761 and GIPR rs1800437, which relate to GLP-1 pathway sensitivity and metabolic factors influencing treatment response.

Genetic predispositions in these pathways do not predict exact medication response or guarantee success, but they can support a more personalized conversation with your provider about whether semaglutide, compounded semaglutide, tirzepatide, or another approach may align with your genetic and clinical profile.

Combining genetic insight with biomarker context—such as fasting glucose, insulin levels, and inflammatory markers—helps you and your provider make informed decisions about which treatment option to explore first and how to adjust dosing or switch compounds if needed.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures